68 related articles for article (PubMed ID: 23613269)
1. Monitoring of minimal residual disease in acute myeloid leukemia with t(8;21)(q22;q22).
Zhang L; Li Q; Li W; Liu B; Wang Y; Lin D; Zhou C; Li C; Wang J; Mi Y
Int J Hematol; 2013 Jun; 97(6):786-92. PubMed ID: 23613269
[TBL] [Abstract][Full Text] [Related]
2. Pontin is a critical regulator for AML1-ETO-induced leukemia.
Breig O; Bras S; Martinez Soria N; Osman D; Heidenreich O; Haenlin M; Waltzer L
Leukemia; 2014 Jun; 28(6):1271-9. PubMed ID: 24342949
[TBL] [Abstract][Full Text] [Related]
3. [Clinical features and prognosis of core binding factor acute myeloid leukemia children in South China: a multicenter study].
Guo BY; Wang Y; Li J; Li CF; Feng XQ; Zheng MC; Liu SX; Yang LH; Jiang H; Xu HG; He XL; Wen H
Zhonghua Er Ke Za Zhi; 2023 Oct; 61(10):881-888. PubMed ID: 37803854
[No Abstract] [Full Text] [Related]
4. Risk-directed therapy based on genetics and MRD improves the outcomes of AML1-ETO-positive AML patients, a multi-center prospective cohort study.
Xu D; Yang Y; Yin Z; Tu S; Nie D; Li Y; Huang Z; Sun Q; Huang C; Nie X; Yao Z; Shi P; Zhang Y; Jiang X; Liu Q; Yu G
Blood Cancer J; 2023 Nov; 13(1):168. PubMed ID: 37957175
[No Abstract] [Full Text] [Related]
5. [Prognostic value of dynamic monitoring of RUNX1-RUNX1T1 transcript in pediatric acute myeloid leukemia].
Gao HT; Zhang Y; Sun K; Guo JM; Chen YQ; Chen XL; Shi J; Niu XN; Wang F; Huo L
Zhonghua Xue Ye Xue Za Zhi; 2017 Mar; 38(3):210-215. PubMed ID: 28395444
[No Abstract] [Full Text] [Related]
6. Protein lysine 43 methylation by EZH1 promotes AML1-ETO transcriptional repression in leukemia.
Dou L; Yan F; Pang J; Zheng D; Li D; Gao L; Wang L; Xu Y; Shi J; Wang Q; Zhou L; Shen N; Singh P; Wang L; Li Y; Gao Y; Liu T; Chen C; Al-Kali A; Litzow MR; Chi YI; Bode AM; Liu C; Huang H; Liu D; Marcucci G; Liu S; Yu L
Nat Commun; 2019 Nov; 10(1):5051. PubMed ID: 31699991
[TBL] [Abstract][Full Text] [Related]
7. CBFbeta is critical for AML1-ETO and TEL-AML1 activity.
Roudaia L; Cheney MD; Manuylova E; Chen W; Morrow M; Park S; Lee CT; Kaur P; Williams O; Bushweller JH; Speck NA
Blood; 2009 Mar; 113(13):3070-9. PubMed ID: 19179469
[TBL] [Abstract][Full Text] [Related]
8. Usefulness of KIT mutant transcript levels for monitoring measurable residual disease in t (8;21) acute myeloid leukemia.
Sun Y; Wang X; Chen WM; Hao Y; Li LD; Li JY; Sun K; Shi ZY; Jiang H; Jiang Q; Huang XJ; Qin YZ
Hematol Oncol; 2024 Mar; 42(2):e3264. PubMed ID: 38461410
[TBL] [Abstract][Full Text] [Related]
9. [Co-existence of AML1-ETO and BCR-ABL1 fusion genes in acute myeloid leukemia: a case report].
Yao YQ; Jia X; Liu H; Lu QS; Xiong WJ; Zhang Y; Liu QF; Shi PC
Zhonghua Nei Ke Za Zhi; 2024 Feb; 63(2):203-206. PubMed ID: 38326048
[TBL] [Abstract][Full Text] [Related]
10. Single-cell RNA sequencing of a new transgenic t(8;21) preleukemia mouse model reveals regulatory networks promoting leukemic transformation.
Yan M; Liu M; Davis AG; Stoner SA; Zhang DE
Leukemia; 2024 Jan; 38(1):31-44. PubMed ID: 37838757
[TBL] [Abstract][Full Text] [Related]
11. [Clinical features and prognosis of core binding factor acute myeloid leukemia in children].
Liu C; Chen XY; Yi MH; Wu WQ; Ruan M; Zhu XF
Zhongguo Dang Dai Er Ke Za Zhi; 2020 Jul; 22(7):739-743. PubMed ID: 32669171
[TBL] [Abstract][Full Text] [Related]
12. A novel AML1-ETO/FTO positive feedback loop promotes leukemogenesis and Ara-C resistance via stabilizing IGFBP2 in t(8;21) acute myeloid leukemia.
Zhou W; Li S; Wang H; Zhou J; Li S; Chen G; Guan W; Fu X; Nervi C; Yu L; Li Y
Exp Hematol Oncol; 2024 Jan; 13(1):9. PubMed ID: 38268050
[TBL] [Abstract][Full Text] [Related]
13. Genomic landscape and clonal evolution of acute myeloid leukemia with t(8;21): an international study on 331 patients.
Christen F; Hoyer K; Yoshida K; Hou HA; Waldhueter N; Heuser M; Hills RK; Chan W; Hablesreiter R; Blau O; Ochi Y; Klement P; Chou WC; Blau IW; Tang JL; Zemojtel T; Shiraishi Y; Shiozawa Y; Thol F; Ganser A; Löwenberg B; Linch DC; Bullinger L; Valk PJM; Tien HF; Gale RE; Ogawa S; Damm F
Blood; 2019 Mar; 133(10):1140-1151. PubMed ID: 30610028
[TBL] [Abstract][Full Text] [Related]
14. Core Binding Factor Leukemia: Chromatin Remodeling Moves Towards Oncogenic Transcription.
Beghini A
Cancers (Basel); 2019 Dec; 11(12):. PubMed ID: 31817911
[TBL] [Abstract][Full Text] [Related]
15. Assessment of acute myeloid leukemia molecular measurable residual disease testing in an interlaboratory study.
Scott S; Dillon R; Thiede C; Sadiq S; Cartwright A; Clouston HJ; Travis D; Mokretar K; Potter N; Chantry A; Whitby L
Blood Adv; 2023 Jul; 7(14):3686-3694. PubMed ID: 36939402
[TBL] [Abstract][Full Text] [Related]
16. Is it time for age and clinically adjusted minimal residual disease interpretation in acute myeloid leukemia?
Ofran Y
Haematologica; 2024 Jan; 109(1):6-7. PubMed ID: 37534509
[No Abstract] [Full Text] [Related]
17. Minimal residual disease monitoring in t(8;21) acute myeloid leukemia based on RUNX1-RUNX1T1 fusion quantification on genomic DNA.
Duployez N; Nibourel O; Marceau-Renaut A; Willekens C; Helevaut N; Caillault A; Villenet C; Celli-Lebras K; Boissel N; Jourdan E; Dombret H; Figeac M; Preudhomme C; Renneville A
Am J Hematol; 2014 Jun; 89(6):610-5. PubMed ID: 24616160
[TBL] [Abstract][Full Text] [Related]
18. Association of hematologic response and assay sensitivity on the prognostic impact of measurable residual disease in acute myeloid leukemia: a systematic review and meta-analysis.
Short NJ; Fu C; Berry DA; Walter RB; Freeman SD; Hourigan CS; Huang X; Gonzalez GN; Hwang H; Qi X; Kantarjian H; Zhou S; Ravandi F
Leukemia; 2022 Dec; 36(12):2817-2826. PubMed ID: 36261575
[TBL] [Abstract][Full Text] [Related]
19. Clinical Outcomes Based on Measurable Residual Disease Status in Patients with Core-Binding Factor Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis.
Rotchanapanya W; Hokland P; Tunsing P; Owattanapanich W
J Pers Med; 2020 Nov; 10(4):. PubMed ID: 33256157
[TBL] [Abstract][Full Text] [Related]
20. Measurable residual disease monitoring provides insufficient lead-time to prevent morphologic relapse in the majority of patients with core-binding factor acute myeloid leukemia.
Puckrin R; Atenafu EG; Claudio JO; Chan S; Gupta V; Maze D; McNamara C; Murphy T; Shuh AC; Yee K; Sibai H; Minden MD; Wei C; Stockley T; Kamel-Reid S; Schimmer AD
Haematologica; 2021 Jan; 106(1):56-63. PubMed ID: 31896684
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
